Eribulin

From WikiMD.org
Jump to navigation Jump to search

Eribulin (pronounced eh-rih-BYOO-lin) is a chemotherapy drug used in the treatment of certain types of cancer, including breast cancer and liposarcoma. It is a synthetic analogue of halichondrin B, a product isolated from the marine sponge Halichondria okadai.

Etymology

The name "Eribulin" is derived from the chemical structure of the drug, which is a simplified version of the natural product halichondrin B. The prefix "Eri-" is derived from the genus name of the sponge from which halichondrin B is isolated, Eribulin.

Pharmacology

Eribulin works by inhibiting the growth phase of microtubule dynamics, which prevents cell division and leads to cell death. This is different from other tubulin inhibitors, which also affect the shortening phase of microtubule dynamics.

Usage

Eribulin is used in the treatment of metastatic breast cancer and liposarcoma that has not responded to other treatments. It is usually given by injection into a vein.

Side Effects

Common side effects of eribulin include fatigue, nausea, hair loss, and low blood cell counts. More serious side effects can include nerve damage, heart problems, and severe infections.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski